Weiss Multi-Strategy Advisers’s Myriad Genetics MYGN Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-10,000	Closed	-$235K	–	1067
2013 Q3	$235K	Hold	10,000	–	–	0.01%	774
2013 Q2	$269K	Buy	+10,000	New	+$290K	0.01%	623

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Weiss Multi-Strategy Advisers's MYGN Position: Q2 2014 in Review

Weiss Multi-Strategy Advisers sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 6,450 shares — an estimated $221K sold.

Weiss Multi-Strategy Advisers first reported a position in MYGN in Q3 2013 and held it in 3 quarters. The position peaked at $336K in Q4 2013. 283 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

Weiss Multi-Strategy Advisers reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 6,450 Myriad Genetics shares in Q2 2014, an estimated $221K.
Weiss Multi-Strategy Advisers first reported a position in Myriad Genetics in Q3 2013 and held it in 3 quarters.
Weiss Multi-Strategy Advisers's Myriad Genetics position peaked at $336K in Q4 2013.
283 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2014, filed 14 Aug 2014.